Organic Active Ingredients TRIZ Cases

Myricetin derivatives from Parrotia persica accelerate wound healing while avoiding inflammatory responses linked to synthetic growth factors.

Novel lipid preparations form stable complexes with nucleic acids, resisting serum-induced aggregation and maintaining delivery capability.

Bi-heteroaryl compounds inhibit Vps34 to sensitize resistant cancer cells to metabolic stress and apoptosis.

Stable aqueous suspension of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone particles prevents precipitation in high water content formulations.

A novel compound regulates epithelial-mesenchymal transition to prevent fibrosis.

A hydrophilic pyrazine derivative emits spectral energy under visible light to assess renal function through direct optical detection.

Specific double-stranded RNA sequences target JAK1 and JAK3 genes to minimize off-target effects while maximizing therapeutic efficacy.

Pyridinone dicarboxamide compounds selectively inhibit bromodomain 2 of BET proteins to treat autoimmune and inflammatory conditions.

Delivering a truncated Dgkk gene via AAV9 vectors overcomes FMRP-mediated repression to restore protein function and improve behavioral phenotypes.

Segmenting ezetimibe and rosuvastatin into separate layers prevents pharmaceutical interactions that decrease dissolution, ensuring stable release profiles.

Inverted core-shell nanoassemblies prevent electron transfer quenching while maintaining colloidal stability for precise bioimaging.

Novel triazolopyridine compounds modulate gamma-secretase activity to alter amyloid beta cleavage patterns.

Screening method identifies beta-adrenergic ligands that increase GLUT4 translocation without elevating cAMP production.

Formula I quinolinone compounds inhibit Syk kinase activity to reduce tumor cell survival.

Benzo-fused heterocycle sulfamide derivatives reduce body weight and delay gastric emptying to treat obesity in patients with BMI 25-30.

Novel 3-pyridyl carboxamide compounds inhibit spleen tyrosine kinase activity to treat inflammatory and autoimmune diseases.

Co-expressing porcine interferon-alpha and gamma in one adenovirus vector halves the required titer, boosting foot-and-mouth disease inhibition.

Allosteric modulators target the M4 receptor to improve therapeutic efficacy while avoiding peripheral cholinergic side effects and hepatotoxicity.

Amino acid excipients stabilize solid caspofungin acetate formulations, eliminating cold chain logistics requirements.

Formula I compounds inhibit peptidylarginine deiminase 4 activity, mitigating pathological citrullination in rheumatoid arthritis and lupus.

Morphinan derivatives target pancreatic NMDA receptors to stimulate insulin release only at elevated glucose concentrations.

A lipid nanoparticle with a pH-sensitive cationic lipid enhances nucleic acid introduction into target cells.

Compounds targeting GCN2 kinase improve treatment effectiveness while reducing adverse side effects in cancer therapy.

Exogenous fucosylated HMOs compensate for FUT2 genetic mutations to increase bifidobacteria abundance and restore gut barrier function.

Drug-eluting sinus scaffolds stabilize openings and prevent tissue adhesion, reducing inflammation without invasive surgery.

Indazole derivatives stimulate endogenous insulin release in response to glucose, reducing hypoglycemia risk while preserving beta-cell function.

Combining an FGFR inhibitor with an anti-PD1 antibody targets urothelial carcinoma through synergistic mechanism.

Antisense oligonucleotides induce exon skipping in VEGF-A pre-mRNA to reduce tumor growth while avoiding antibody side effects.

Papaverine derivatives block mitochondrial complex I to reduce tumor oxygen consumption, overcoming hypoxia-induced radiation resistance in cancer treatment.

KRAS mutation status predicts patient sensitivity to Cdc7 kinase inhibitors, reducing ineffective treatments and resource waste.

A stable injectable composition uses specific bile acid ratios to selectively induce apoptosis in adipocytes.

Optimized Lonicera Japonica flower water extract with secoxyloganin treats Helicobacter pylori infection while avoiding antibiotic resistance and side effects.

Modified CAPH peptides penetrate mammalian cells via electrostatic interactions, destroying intracellular microbes while minimizing host cytotoxicity.

Macrocyclic compounds inhibit the hepatitis C virus NS3 protease to overcome limited clinical benefits of current therapies.

aPKC inhibitors target atypical protein kinase C to reduce dietary-induced obesity and improve glucose metabolism without harsh side effects.

Segmented microneedles penetrate dense scalp barriers to deliver aptamers via hybridization kinetics, eliminating invasive injection procedures.

Tradipitant targets substance P via NK-1 antagonism to prevent cytokine storms and acute respiratory distress syndrome.

Incorporating antioxidant additives into furandicarboxylate monomers prevents oxidative yellowing, maintaining polymer clarity for packaging applications.

Cyclodextrins solubilize hydrophobic imiquimod in aqueous cores, resolving low pH solubility barriers for injectable co-formulation.

Guanidine derivatives activate PPARδ transcriptional activity by forming hydrogen bonds with specific amino acid residues in the ligand-binding pocket.

IDO1 inhibitors suppress pathological neovascularization in retinopathy while preserving normal vascular development through local immunometabolic modulation.

Specific WEE1 kinase inhibitors disrupt the G2 checkpoint to induce mitotic catastrophe, sparing normal cells with intact G1 checkpoints.

GGTI-2417 upregulates p27Kip1 to overcome Rho-mediated downregulation and induce apoptosis in breast tumors.

Generating transplantable beta cells via FoxO1 and Wnt inhibitors to overcome the critical shortage of pancreatic islet donors.

Selected Bifidobacterium longum strain expresses exopolysaccharides with 6-deoxy tallose to resolve gastrointestinal survival and bile tolerance contradictions.

Crystalline form G of a tyrosine kinase inhibitor resolves stability limitations by maintaining structural integrity under heat and light exposure.

A soluble microneedle system dissolves in skin to deliver active ingredients for muscle relaxation.

Free-radical depolymerization and sulfation of marine exopolysaccharides yield derivatives that inhibit lung metastases without heparin-induced bleeding risks.

ATR kinase inhibition rescues neurons and eliminates detrimental immune cells, reducing infarct size and improving neurological function in ischemic stroke.

Topically active corticosteroid reduces systemic side effects while treating eosinophilic esophagitis through localized delivery.

Novel SHP-1 agonist compounds enhance phosphatase activity to overcome resistance from constitutively active kinase mutations.

Porous partitions separate soluble drug forms from insoluble matter in implantable reservoirs, preventing exit port clogging during sustained delivery.

Polymer-coated drug implants release therapeutics in the cochlea to prevent ototoxicity and hearing loss without systemic side effects.

Inhibiting UBE2N reduces TRAF6 protein levels to induce cell death in myelodysplastic syndrome and acute myeloid leukemia cells.

Fraxinus angustifolia extracts reverse dysbiosis and reduce liver fat deposition, addressing NAFLD and NASH progression.

N-acetylhydroxyproline intercepts glycation intermediates via pyridoxamine mediation, preserving tissue elasticity and preventing skin aging damage.

A pyrrolopyrimidinone carboxamide derivative inhibits cyclin-dependent kinases to induce apoptosis in hepatocellular carcinoma cells.

Encapsulating finasteride in polymeric nanocapsules improves drug stability and bioavailability at hair follicles.

Permeation enhancers boost jejunal uptake of oral DTPA chelates, overcoming low bioavailability from hydrophilicity.

Isolated fulvate fractions combined with growth factors enhance transdermal delivery efficiency, addressing slow healing rates in complex wounds.

Bunazosin ophthalmic preparation stabilizes refractive index and axial length to prevent myopia progression in school-age children.

Combining BCL-2 inhibitors with rituximab and bendamustine targets multiple signaling pathways to enhance anti-tumor activity.

A lipid composition self-assembles at the air-tear interface to form an anti-evaporative barrier.

Inhibiting the mitochondrial pyruvate carrier during culture resolves the persistence-proliferation trade-off, enhancing CAR-T durability.

Replacing chromium trioxide with an alkali hypochlorite and t-alkyl hydrogen peroxide mixture eliminates toxic residues while maintaining high purity.

Hydrophilic exterior nanoparticles encapsulate platinum(IV) precursors to resolve hydrophilic drug incompatibility with delivery matrices.

Pyridino[1,2-a]pyrimidinone analogs inhibit PI3K and mTOR simultaneously to overcome drug resistance in cancer treatment.

Nanoparticle dactinomycin reduces side effects while improving treatment efficacy for myelodysplastic syndrome and acute myeloid leukemia.

Fraxinus excelsior seed extract containing secoiridoids activates PPAR-alpha to manage type 2 diabetes and obesity.

CFI-400945 selectively inhibits polo-like kinase 4 to suppress tumor growth while sparing non-tumor cells, reducing toxicity from conventional therapies.

CD9P-1 peptide fragments degrade CD151 to inhibit angiogenesis, avoiding secondary effects from current VEGF treatments.

An oral pouch product blends sugar alcohol with a cooling agent at a specific weight ratio to deliver a cool sensation while maintaining composition stability.

Carboxylate-substituted amino triazoles inhibit acidic mammalian chitinase to address airway remodeling in asthma where standard therapies fail.

Administering Saccharomycopsis fibuligera probiotics and Dectin-1 genotyping assays addresses neglected fungal roles in immune responses and colitis severity.

A Type A crystalline solid form of olutasidenib provides enhanced chemical stability and moisture resistance for pharmaceutical applications.

A pharmaceutical compound selectively inhibits Nav1.7 sodium channels to block pain signaling in peripheral nociceptors.

Gallic acid treats metabolic disorders by simultaneously addressing disturbances in bile acid, amino acid, and gut microbiota metabolism.

Microbial fermented sodium hyaluronate fragments paired with astaxanthin alleviate osteoarthritis symptoms by neutralizing free radicals.

Pyridazine derivatives selectively inhibit 11beta-HSD1 to lower blood glucose and normalize lipids without triggering side effects from 11beta-HSD2 inhibition.

Compound I inhibits APOL1 activity to treat focal segmental glomerulosclerosis and non-diabetic kidney disease.

High-Z metal ions in metal-organic frameworks enhance X-ray absorption, enabling precise tumor destruction while reducing toxicity to normal tissues.

Divided catalyst dosing during dissolution and crystallization minimizes compound loss into mother liquor.

Bcl-2 family inhibitors selectively kill senescent cells, reducing tissue damage and delaying aging disorders.

A liposomal pharmaceutical composition achieves high encapsulation efficiency for antipsychotic drugs using a specific molar ratio of drug to lipid.

Chemically modified double-stranded RNAi agents silence transthyretin gene expression to treat amyloidosis.

A quinazoline derivative binds covalently to EGFR receptors to inhibit autophosphorylation and cell cycle progression.

Steroidal C-17 benzoazoles reduce tumor volume by 93.8% while avoiding side effects from modest existing inhibitors.

Formula I azetidinone compounds inhibit intestinal cholesterol absorption, reducing coronary heart disease risk beyond statin therapy alone.

Non-aqueous zolpidem formulation maintains stability over two years while achieving Tmax under 20 minutes through reduced penetration enhancers.

Cap-ON and Cap-OFF complex ratios predict BRAF inhibitor resistance, enabling personalized combination therapy.